


1. -22. (Canceled)

23. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond,  $(CH_2)_n$ ,  $O$ ,  $S$ , or  $O(CH_2)_n$ ,  $O$ , or  $O(CH_2)_n$ ,

wherein  $n=1-6$ ;

$R_1=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ ;


$R_2=F$  or  $COOR_5$ ,

wherein  $R_5$  is  $C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ ;

$R_3=CH_3$  or  $(CH_2)_n-COOR_6$ ,

wherein  $n=1-6$  and  $R_6$  is  $C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ ;

$R_4=(CH_2)_n-COOR_7$ ,  $R_8-(CH_2)_n-R_{10}$ ,  $R_{11}$  or



$R_7=O$ ,  $NH$ , or  $NR_9$ ,

$R_8$ =optionally substituted aryl or heterocycle,

$R_9=C_{4-6}$  alkyl,

$R_{10}=O$ ,  $S$ ,  $SO$ ,  $SO_2$ ,  $NH$ , or  $NR_{12}$ ,

$R_{11}$ =aryl or heterocyclyl optionally substituted with  $(CH_2)_n$   $COOR_{14}$ ,

$R_{12}=C_{4-6}$  alkyl, optionally substituted with OH or  $NH_2$ ,

$R_{13}=C_{4-6}$  alkyl, optionally substituted with OH or  $NH_2$ ,


$R_{14}=C_{4-6}$  alkyl, optionally substituted with OH or  $NH_2$ ,

$R_{15}=(CH_2)_n$   $COOR_{16}$ ,

$R_{16}=C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ , and


$R_{17}$ =not present or  $COOR_{18}$  wherein  $R_{18}$  is  $C_{1-6}$  alkyl, optionally substituted with OH or  $NH_2$ , and wherein  $n=1-6$ .

24. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has a formula selected from the group consisting of:




X=bond,  $CH_2$ , or  $OCH_2$

R=lower alkyl optionally substituted OH or  $NH_2$ ;




R=lower alkyl optionally substituted by OH or  $NH_2$ ;




$n=1$  to  $3$

R=lower alkyl optionally substituted by OH or  $NH_2$ ;




$n=1$  to  $3$

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>; and




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>; ~~NH<sub>2</sub>~~



~~n=1 to 3 X=O, NH, NR where R is lower alkyl~~

~~Y=optionally substituted aryl or heterocyclyl; and~~




~~n=0 to 2~~

~~X=O, S, SO, SO<sub>2</sub>, NH NR or N(CH<sub>2</sub>)<sub>m</sub>COOH where m is 0 or 2~~

~~Y=aryl or heterocyclyl substituted with (CH<sub>2</sub>)<sub>m</sub>COOH where m is 0 to 2.~~


25. (Original) The compound, according to claim 24, wherein said compound has the following structure:



X=bond, CH<sub>2</sub>, or OCH<sub>2</sub>


R=lower alkyl optionally substituted OH or NH<sub>2</sub>.

26. (Original) The compound, according to claim 24, wherein said compound has the following structure:



R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.


27. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.


28. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.

29. (Original) The compound, according to claim 24, wherein said compound has the following structure:




R=lower alkyl optionally substituted by OH or NH<sub>2</sub>.

30. – 31. (Canceled)

32. (Previously Presented) The method, according to claim 23, wherein the patient is a human.

33. (Previously Presented) The method, according to claim 23, wherein said method is used to treat a condition selected from the group consisting of hypertension, angina, ischemia, arrhythmia, congestive heart failure, and cardiac insufficiency.

34. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond, (CH<sub>2</sub>)<sub>n</sub>, O, S, or O(CH<sub>2</sub>)<sub>n</sub>, O, or O(CH<sub>2</sub>)<sub>n</sub>,

wherein n=1-6;

R<sub>1</sub>=C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;


R<sub>2</sub>=F or COOR<sub>5</sub>,

wherein R<sub>5</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>3</sub>=CH<sub>3</sub> or (CH<sub>2</sub>)<sub>n</sub>--COOR<sub>6</sub>,

wherein n=1-6 and R<sub>6</sub> is C<sub>1-6</sub> alkyl, optionally substituted with OH or NH<sub>2</sub>;

R<sub>4</sub>=(CH<sub>2</sub>)<sub>n</sub>--COR<sub>7</sub>, R<sub>4</sub>=(CH<sub>2</sub>)<sub>n</sub>--R<sub>10</sub>, R<sub>4</sub>=(CH<sub>2</sub>)<sub>n</sub>--R<sub>11</sub>, or



$R_7 = O, NH, \text{ or } NR_9$ ,

$R_8 = \text{optionally substituted aryl or heterocycle}$ ,

$R_9 = C_{4-6}\text{-alkyl}$ ,

$R_{10} = O, S, SO, SO_2, NH, \text{ or } NR_{12}$ ,

$R_{11} = \text{aryl or heterocyclyl optionally substituted with } (CH_2)_n COOR_{14}$ ,

$R_{12} = C_{4-6}\text{-alkyl, optionally substituted with OH or } NH_2$ ,


$R_{13} = C_{4-6}\text{-alkyl, optionally substituted with OH or } NH_2$ ,

$R_{14} = C_{4-6}\text{-alkyl, optionally substituted with OH or } NH_2$ ,

$R_{15} = \text{is H}$ ,

$R_{17} = \text{not present or } COOR_{18} \text{ wherein } R_{18} \text{ is } C_{1-6} \text{ alkyl, optionally substituted with OH or } NH_2, \text{ and}$   
 wherein  $n=1-6$ ,  $n=1-6$ ;

provided that when  $R_2$  is fluoro;  $X$  is O;  $R_3$  is methyl,  $(CH_2)_{0-4}$ , OR  $R_4$  is  $(CH_2)_n O C_{4-6}\text{-alkyl}$ ;

and  $R_4$  is , where  $n$  is 3 and  $R_{15}$  is H; then  $R_{17}$  is  $COOR_{18}$ .